The short version
- Why people research itFocus, memory, neuroprotection, mood and stress resilience.
- What the evidence isThere is nothing to cite.
- What to watchUnusual fatigue or exercise intolerance.
How J-147 works
J-147 is interesting for a reason that has nothing to do with its structure: it was not designed against amyloid. Twenty years of Alzheimer's drug development aimed at a single protein and mostly failed.
The chemistry. J-147 is a synthetic derivative of curcumin, retaining the pharmacophore that gave curcumin its activity in neuroprotection assays while removing the properties that made curcumin useless as a drug: negligible oral bioavailability, rapid conjugation and poor brain penetration. The compound is curcumin's activity without curcumin's pharmacokinetics, which is a much more useful description than calling it a curcumin analog Qiu 2023.
Its target was identified as mitochondrial ATP synthase — modestly inhibiting it triggers an adaptive stress response that raises mitochondrial calcium buffering and downstream NGF and BDNF. It was selected in ageing-brain models rather than amyloid models, which is why its profile reads differently from the Alzheimer's drugs it sits beside.
- Oral
On the goal map: Cerebral metabolism & blood flow (Focus, memory & cognition)
Research on J-1474 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Preclinical (extensive rodent, Salk Institute); early human safety work.
Human clinical evidence
There is nothing to cite. Which is the conservative direction, but neither figure was established in a person.
Correlative data
Curcumin itself has a long record of poor oral bioavailability and poor brain penetration — the problem J-147 was built to solve. Read the parent compound's disappointing trial history as context for why a derivative was needed, not as evidence the derivative works.
How the mechanism reads
Its molecular target was identified as mitochondrial ATP synthase. Modestly inhibiting it triggers an adaptive stress response that raises mitochondrial calcium buffering and downstream NGF and BDNF — a hormetic mechanism rather than a blocking one.
MechanisticIt was selected in ageing-brain models rather than amyloid models, which is why its preclinical profile reads differently from the Alzheimer's drugs it sits beside. Extensive rodent data; almost no human data.
Experimental, animal or cell
Sources
- Qiu F, et al. Current evidence for J147 as a potential therapeutic agent in nervous system disease: a narrative review. BMC Neurology 2023 · PMID 37674139
- Qiu F, et al. J147 ameliorates sepsis-induced depressive-like behaviors in mice by attenuating neuroinflammation through regulating the TLR4/NF-kappaB signaling pathway. Journal of Molecular Histology 2023 · PMID 37676534
- Austad SN, et al. Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease. Acta Pharmaceutica Sinica B 2022 · PMID 35256932
- Patro S, et al. ATP Synthase and Mitochondrial Bioenergetics Dysfunction in Alzheimer's Disease. International Journal of Molecular Sciences 2021 · PMID 34681851
- Rahman MA, et al. Drug Target to Alleviate Mitochondrial Dysfunctions in Alzheimer's Disease: Recent Advances and Therapeutic Implications. Current Neuropharmacology 2024 · PMID 39234772
J-147 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Mitochondrial disease, since it partly inhibits ATP synthase.
- Liver disease, as the curcumin-derived molecule is processed hepatically with no human data.
- Active cancer, as altering energy handling can matter both ways.
- Pregnancy or under 18, with no human safety data at all.
What’s expected
- An adaptive stress response from mild ATP synthase inhibition, raising mitochondrial calcium buffering.
- Brain neurotrophic signaling in mouse studies.
- No human effect has been measured.
Watch for
- Unusual fatigue or exercise intolerance.
- Muscle weakness or cramps.
- Persistent headaches.
Labs that tell you it’s working
- Comprehensive Metabolic Panel: bicarbonate and liver enzymes capture energy-metabolism stress.
- HbA1c: mouse studies reported whole-body metabolic shifts.
- hs-CRP: inflammation read for an unstudied molecule.
Curcumin-derived molecule targeting mitochondrial ATP synthase; modest inhibition triggers an adaptive stress response, with no published human safety data. PMID 35256932 PMID 37674139
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
J-147 FAQ4 common questions
- Is J-147 approved for human use?
- No. J-147 is a research compound.
- What is J-147 researched for?
- Focus, memory, neuroprotection, mood and stress resilience.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; HbA1c; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for J-147: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



